ReviewTherapeutic advances in chronic disease2014
Cardiovascular impact of drugs used in the treatment of diabetes.
Review in Therapeutic advances in chronic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02491333 (The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance), which is not on this map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Acupuncture on Insulin Sensitivity of Women With Polycystic Ovary Syndrome and Insulin Resistance: a Randomized Controlled Trial
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cardiovascular benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2025 · on this mapPooled it
- Trial
- In vivo and in silico study of europinidin against streptozotocin-isoproterenol-induced myocardial damage via alteration of hs-CRP/CPK-MB/Caspase-3/Bcl-2 pathways.Scientific reports · 2025Article
- Disease Risk Score Derivation and Validation in Abu Dhabi, United Arab Emirates: A Retrospective Cohort Study.Journal of the American Heart Association · 2024Article
- The Impact of Genetically Proxied AMPK Activation, the Target of Metformin, on Functional Outcome Following Ischemic Stroke.Journal of stroke · 2023Article
- Review
- Synthesis, Antioxidant, and Antidiabetic Activities of Ketone Derivatives of Succinimide.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Diabetes: Chronic Metformin Treatment and Outcome Following Acute Stroke.Frontiers in neurology · 2022Article
- Association between fasting insulin and C-reactive protein among adults without diabetes using a two-part model: NHANES 2005-2010.Diabetology & metabolic syndrome · 2021Article
- Dual anticancer role of metformin: an old drug regulating AMPK dependent/independent pathways in metabolic, oncogenic/tumorsuppresing and immunity context.American journal of cancer research · 2021Review
- Amelioration of Endothelial Dysfunction in Diabetes: Role of Takeda G Protein-Coupled Receptor 5.Frontiers in pharmacology · 2021Review
- A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity.BMB reports · 2020Review
- Biological Activities of Selected Plants and Detection of Bioactive Compounds fromMolecules (Basel, Switzerland) · 2020Article
- Obesity preventive function of novel edible mushroom,Journal of traditional and complementary medicine · 2020Article
- Article
- Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis.Diabetes care · 2017Article
- Cardiovascular benefits of the newer medications for treating type 2 diabetes mellitus.Journal of thoracic disease · 2017Review
- Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy.Frontiers in cardiovascular medicine · 2017Review
- Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.Cardiovascular diabetology · 2016Review
- A Study on the Level of Oxidative Stress and Inflammatory Markers in Type 2 Diabetes Mellitus Patients with Different Treatment Modalities.Journal of clinical and diagnostic research : JCDR · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The International Diabetes Federation predicts that by 2035 10% of the population of the world will have been diagnosed with diabetes, raising serious concerns over the resulting elevated morbidity and mortality as well as the impact on health care budgets. It is also well recognized that cardiovascular disease is the primary cause of the high morbidity and mortality associated with diabetes, raising the concern that appropriate drug therapy should not only correct metabolic dysfunction, but also protect the cardiovascular system from the effects of, in particular, the epigenetic changes that result from hyperglycaemia. A number of new classes of drugs for the treatment of diabetes have been introduced in the past decade, providing the opportunity to optimize treatment; however, comparative information of the cardiovascular benefits, or risks, of the newer drugs versus older therapies such as metformin is variable. This review, in addition to summarizing the cellular basis for the therapeutic action of these drugs, addresses the evidence for their cardiovascular benefits and risks. A particular focus is provided on metformin as it is the first choice drug for most patients with type 2 diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.